Kidney Cancer

Watch Dr. Vitaly Margulis, from UT Southwestern Medical Center, discuss staging, during the CURE Educated Patient Kidney Cancer Summit.

From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.

MRX0518 plus Keytruda led to a clinical benefit in four out of 16 evaluable patients with renal cell carcinoma. The drug duo will continue to be studied for multiple types of solid tumors.

One patient with stage 4 kidney cancer pivoted from being a journalist to a patient advocate, educating patients and others about a cancer that requires more awareness and research funding.

In a recent clinical trial, treatment with Bavencio plus Inlyta produced promising outcomes in the presurgical treatment of patients with non-metastatic, clear cell renal cell carcinoma.

Treatment with Cabometyx before surgery in patients with advanced renal cell carcinoma, a type of kidney cancer, may provide benefits, although further research is required before a decision is made about its role in presurgical treatment.

Although the data failed to identify a predictive biomarker in patients with advanced kidney cancer, an expert from Memorial Sloan Kettering Cancer Center in New York notes that the results indicate that no one should be excluded from receiving Lenvima plus Keytruda.

Fotivda – a TKI drug that was approved last year – not only improved survival outcomes, but was also very tolerable in terms of side effects for patients with metastatic renal cell carcinoma.

At a 30-month follow-up, patients with renal cell carcinoma — which is the most common type of kidney cancer — who underwent nephrectomy continued to benefit from Keytruda after the surgical removal of the affected kidney.

Opdivo plus Cabometyx prolonged survival with minimal effects to their health status, which may highlight the need for patients to advocate for their quality of life when making treatment decisions.

When Joseph Heisler was diagnosed with von Hippel-Lindau disease 30 years ago, there was hardly any information on the condition. Fast forward three decades, there is an FDA-approved drug and a handbook of information available in two languages.

The STELLAR-002 trial is currently underway to examine the combination of XL092, an experimental tyrosine kinase inhibitor, in combination with immuno-oncology therapies for patients with advanced solid tumors.

As the standard treatment for patients with renal cell carcinoma, the most common type of kidney cancer, related to VHL disease is often surgical procedures, the use of Welireg may reduce surgical burden in patients.

The use of immunotherapy in patients with advanced cancers and decreased fitness levels or organ function increased from 2014 to 2019, although trials for this treatment typically exclude this population.

2021 was full of research advancements and FDA drug approvals that continue to improve cancer care for patients with a variety of malignancies.

Take a look back at some of the major milestones in kidney cancer that were achieved in 2021.

Although the recent FDA approval of Keytruda was exciting for high-risk, nonmetastatic renal cell carcinoma, an expert from The University of MD Anderson Cancer Center notes more work is needed, particularly when it comes to individualizing treatment.

Treatment-free survival with Opdivo and Yervoy was more than twice as long when compared with Sutent alone in patients with kidney cancer.

Radiation therapy in place of systemic therapy may improve quality of life and treatment costs for patients with renal cell carcinoma.

Some patients with kidney cancer do not need to rush into the operating room, explained Dr. Alexander Kutikov.

The approval follows statistically significant improved disease-free survival results.

From microbiome-based therapies to reinventing an old drug and more, an expert from City of Hope explains the interest around emerging treatment options and approaches in metastatic kidney cancer.

An expert discusses how the kidney cancer treatment landscape has changed over the last few years, although the number of options available for patients may make it somewhat confusing to navigate.

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, about the treatment options for patients with VHL.

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, to better understand VHL and its impact on cancer.

As a part of its “Speaking Out” video series, CURE spoke with Stacy Lloyd on behalf of the VHL Alliance, about discussing hereditary cancer with family members and how a diagnosis can lead to earlier surveillance for the disease.

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, about disparities seen in VHL and its patient population.

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, about VHL as a rare disease and resources available for patients to learn more.

Some patients with kidney cancer who are at a high risk of disease recurrence may benefit from adjuvant therapy; however, it is important recognize the potential side effects.

An expert explains the various treatment options available for a patient who is diagnosed with a small renal mass.